La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
IDEXX Laboratories Bilan de santé
Santé financière contrôle des critères 6/6
IDEXX Laboratories has a total shareholder equity of $1.6B and total debt of $944.9M, which brings its debt-to-equity ratio to 59.8%. Its total assets and total liabilities are $3.4B and $1.8B respectively. IDEXX Laboratories's EBIT is $1.1B making its interest coverage ratio 51. It has cash and short-term investments of $401.6M.
Informations clés
59.8%
Ratio d'endettement
US$944.86m
Dette
| Ratio de couverture des intérêts | 51x |
| Argent liquide | US$401.59m |
| Fonds propres | US$1.58b |
| Total du passif | US$1.83b |
| Total des actifs | US$3.41b |
Mises à jour récentes de la santé financière
IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11
IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24Recent updates
IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Aug 12A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital
Jul 02Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Jun 28Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jun 04Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?
May 21IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 03What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You
Apr 27IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jan 30IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jan 15IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit
Dec 31IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Oct 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 10Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jul 04These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Apr 05Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Jan 05Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Sep 20IDEXX Laboratories: Outstanding Business, But Valuation Is Key
Aug 15These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
Aug 15IDEXX Laboratories Stock Is Very Expensive
Aug 08IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M
Aug 02Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?
Jul 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today
Jul 12Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jun 16IDEXX Laboratories: Great Business, But Still Overvalued
May 25We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
May 06Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth US$474 Based On Its Intrinsic Value?
Apr 23With EPS Growth And More, IDEXX Laboratories (NASDAQ:IDXX) Is Interesting
Apr 09Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Mar 07Analyse de la situation financière
Passif à court terme: Les actifs à court terme de IDXX ( $1.5B ) dépassent ses passifs à court terme ( $1.1B ).
Passif à long terme: Les actifs à court terme de IDXX ( $1.5B ) dépassent ses passifs à long terme ( $717.9M ).
Historique et analyse du ratio d'endettement
Niveau d'endettement: IDXX's net debt to equity ratio (34.4%) is considered satisfactory.
Réduire la dette: Le ratio d'endettement de IDXX a été réduit de 555% à 59.8% au cours des 5 dernières années.
Couverture de la dette: IDXX's debt is well covered by operating cash flow (102.6%).
Couverture des intérêts: IDXX's interest payments on its debt are well covered by EBIT (51x coverage).